stockportfolio.pro
Stocks / ETON vs TBPH
ETON vs TBPH
Eton Pharmaceuticals, Inc. and Theravance Biopharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Eton Pharmaceuticals, Inc. (ETON) | Theravance Biopharma, Inc. (TBPH) | |
|---|---|---|
| Market cap | $0.9B | $0.8B |
| Revenue (latest FY) | $79.95M | $107.46M |
| Net income (latest FY) | $-4.60M | $105.89M |
| Revenue growth (5y CAGR) | 359.6% | 8.4% |
| Net margin | -5.8% | 98.5% |
| Return on equity | -17.6% | 35.7% |
| P/E ratio | — | 7.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ETON — free Open TBPH — freeFrequently asked questions
Which is bigger, ETON or TBPH?
Eton Pharmaceuticals, Inc. is larger by market capitalization — $0.9B versus $0.8B.
Which grows faster, ETON or TBPH?
Over the last five fiscal years, Eton Pharmaceuticals, Inc. grew revenue faster — 359.6%/yr versus 8.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.